We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

13 hedge funds and large institutions have $6.04M invested in AYTU BioPharma in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,498% more capital inflows, than outflows

Capital inflows: $1.77M | Capital outflows: $111K

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

44% more funds holding

Funds holding: 9 → 13 (+4)

5.18% more ownership

Funds ownership: 14.01% → 19.2% (+5.2%)

Holders
13
Holders Change
+4
Holders Change %
+44.44%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wexford Capital
Wexford Capital
Florida
+$1.18M
2
Searle & Co
Searle & Co
Connecticut
+$355K
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$75.8K
4
Bank of America
Bank of America
North Carolina
+$56K
5
BlackRock
BlackRock
New York
+$36.2K

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$72K
2
Virtu Financial
Virtu Financial
New York
-$30K
3
UBS Group
UBS Group
Switzerland
-$8.76K

AYTU Hedge Fund Activity: Q2 2019 in Review

13 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2019, worth a combined $6.04M — up 55% from $3.9M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AYTU positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Wexford Capital, adding an estimated $1.18M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $72K sold.

  • 13 institutional investors held AYTU BioPharma (AYTU) as of Q2 2019, up from 9 in Q1 2019.
  • Funds reported $6.04M of AYTU BioPharma stock for Q2 2019, up 55% quarter-over-quarter.
  • 6 funds opened new AYTU BioPharma positions in Q2 2019 and 2 closed out, a net change of +4 holders.
  • The largest AYTU BioPharma buyer in Q2 2019 was Wexford Capital, an estimated $1.18M added.
  • The largest AYTU BioPharma seller in Q2 2019 was Acadian Asset Management, an estimated $72K sold.

Based on aggregated 13F filings for Q2 2019.